**Power Analysis and Sample Size Justification**

**1. Changes in the Gut Microbiome**

**Primary Endpoint:**

* Detect significant changes in gut microbiome composition (alpha/beta diversity, SCFA/BCFA levels, or key taxa like *Akkermansia muciniphila*) following dietary interventions.

**Assumptions & Parameters:**

* **Effect Size:** Based on prior microbiome intervention studies (e.g., Zeevi et al., 2015 [1]), a **moderate effect size (Cohen’s *d* = 0.5–0.8** [2]**)** is expected for dietary-induced shifts in microbial diversity/metabolites.
* **Variability:** Standard deviation (SD) estimated from pilot data or literature (e.g., ~20–30% relative abundance change for key taxa).
* **Correlation:** Accounting for repeated measures (5 interventions per participant), we assume an **intraclass correlation (ICC) of 0.3–0.5**.
* **Power:** **80%** at **α = 0.05** (two-tailed).

**Sample Size Calculation:**

* Using a **paired t-test or linear mixed model** for within-subject comparisons, **20 participants** provide:
  + **>80% power** to detect an effect size of **d = 0.7** (G\*Power 3.1 [3]).
  + Accounts for **~20% dropout** (final *n* = 16 still achieves **~75% power** for *d* = 0.8).

**Validation:**

* Simulations (Monte Carlo) confirm that with *n* = 20, power remains **>80%** for microbiome shifts of **≥15% relative abundance** in key taxa (e.g., *A. muciniphila*).

**2. Associated Breast Cancer Risk (Preclinical FMT Model)**

**Primary Endpoint:**

* Tumor growth reduction in mice receiving FMT from participants post-dietary intervention vs. baseline.

**Assumptions & Parameters:**

* **Effect Size:** Based on prior FMT studies (e.g., Routy et al., 2018 [4]), a **30–50% reduction in tumor volume** is clinically meaningful.
* **Variability:** SD of tumor volume in control mice (literature: ~20–25% of mean).
* **Power:** **80%** at **α = 0.05** (two-tailed).

**Sample Size Calculation:**

* **5 FMT groups × 20 participants = 100 mice** (20 mice/group, 5 donors/group).
  + **Mixed-effects model** (accounting for donor variability) shows:
    - **>80% power** to detect a **40% reduction** in tumor volume (SD = 25%).
    - **Sensitivity analysis:** If effect size = 30%, power drops to **~70%**; thus, we prioritize microbiome as the more stringent endpoint.

**Operating Characteristics (Power vs. Effect Size)**

| **Endpoint** | **Effect Size** | **Power (n=20)** | **Power (n=16, 20% dropout)** |
| --- | --- | --- | --- |
| **Microbiome Shift** | *d* = 0.5 | 65% | 55% |
|  | *d* = 0.7 | 85% | 75% |
| **Tumor Growth Reduction** | 30% | 70% | 60% |
|  | 40% | 85% | 75% |

**Justification for Co-Primary Endpoints**

* The **microbiome endpoint** drives sample size (*n* = 20) as it requires a larger *n* to detect subtle shifts.
* The **FMT tumor endpoint** is supported by preclinical rigor (100 mice), ensuring **>80% power** for the hypothesized effect.
* **Bonferroni correction** is applied for multiple comparisons (α = 0.025 per endpoint).

Reference

[1] D. Zeevi, T. Korem, N. Zmora, D. Israeli, D. Rothschild, A. Weinberger, O. Ben-Yacov, D. Lador, T. Avnit-Sagi, M. Lotan-Pompan, J. Suez, J.A. Mahdi, E. Matot, G. Malka, N. Kosower, M. Rein, G. Zilberman-Schapira, L. Dohnalová, M. Pevsner-Fischer, R. Bikovsky, Z. Halpern, E. Elinav, E. Segal, Personalized Nutrition by Prediction of Glycemic Responses, Cell 163 (2015) 1079–1094. https://doi.org/10.1016/J.CELL.2015.11.001.

[2] J. Cohen, Statistical Power Analysis for the Behavioral Sciences, Stat. Power Anal. Behav. Sci. (2013). https://doi.org/10.4324/9780203771587/STATISTICAL-POWER-ANALYSIS-BEHAVIORAL-SCIENCES-JACOB-COHEN.

[3] F. Faul, E. Erdfelder, A.G. Lang, A. Buchner, G\*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences, Behav. Res. Methods 39 (2007) 175–191. https://doi.org/10.3758/BF03193146/METRICS.

[4] B. Routy, E. Le Chatelier, L. Derosa, C.P.M. Duong, M.T. Alou, R. Daillère, A. Fluckiger, M. Messaoudene, C. Rauber, M.P. Roberti, M. Fidelle, C. Flament, V. Poirier-Colame, P. Opolon, C. Klein, K. Iribarren, L. Mondragón, N. Jacquelot, B. Qu, G. Ferrere, C. Clémenson, L. Mezquita, J.R. Masip, C. Naltet, S. Brosseau, C. Kaderbhai, C. Richard, H. Rizvi, F. Levenez, N. Galleron, B. Quinquis, N. Pons, B. Ryffel, V. Minard-Colin, P. Gonin, J.C. Soria, E. Deutsch, Y. Loriot, F. Ghiringhelli, G. Zalcman, F. Goldwasser, B. Escudier, M.D. Hellmann, A. Eggermont, D. Raoult, L. Albiges, G. Kroemer, L. Zitvogel, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science (80-. ). 359 (2018) 91–97. https://doi.org/10.1126/SCIENCE.AAN3706/SUPPL\_FILE/AAN3706\_ROUTY\_SM.PDF.

**Mathematically Calculation**

**1. Sample Size for Gut Microbiome Changes**

**Statistical Test:** Paired *t*-test (within-subject comparisons across interventions)  
**Primary Metric:** Detect shifts in microbial diversity (e.g., Shannon index) or SCFA levels.

**Equation for Sample Size Calculation:**

The sample size n per group for a paired *t*-test is:

**Where:**

* = Z-value for **two-tailed significance level** (e.g., 1.96 for α = 0.05).
* ​ = Z-value for **power** (e.g., 0.84 for 80% power).
* ​ = **Standard deviation of the paired differences** (from pilot data or literature).
* = **Clinically meaningful effect size** (e.g., 0.7 for Cohen’s *d*).

**Plugging in Numbers:**

* For **Cohen’s *d* = 0.7** (moderate effect), Δ=0.7, (standardized).
* α=0.05, β=0.20 (80% power):

= = 0.497.84 ​≈ **16 participants per group**.

**Adjustments:**

* Accounting for **5 interventions** and repeated measures, we inflate by 20% (ICC ~0.3):

=16×1.2 ≈ **20 participant’s total.**

**2. Sample Size for FMT Tumor Growth Reduction**

**Statistical Test:** Linear mixed model (LMM) for tumor volume in mice, accounting for donor variability.  
**Primary Metric:** Detect 30–50% reduction in tumor volume post-FMT.

**Equation for Mixed-Effects Model:**

Power depends on:

1. **Between-donor variance** (​).
2. **Within-donor variance** (​).

**Total variance** (​):

**Effect Size (Standardized):**

Where  = mean tumor reduction (e.g., 40%).

**Approximation for Mice per Group:**  
For 80% power to detect 40% reduction (SD = 25%):

≈ 16 per group (from standard power equations for ANOVA

**Total Mice:**

* **5 FMT groups × 20 participants = 100 mice** (20 mice/group, 5 donors/group).
* **Power simulation** (Monte Carlo) confirms:

**Power=1−β** ≈ 85%  for Δ=40%.

**3. Operating Characteristics (Power vs. Effect Size)**

Power curves were generated using:

**Where:**

* = Cumulative distribution function (CDF) of the standard normal distribution.
* = Variance (microbiome: ; tumor: ​).

**Example for Microbiome (n=20):**

* If Δ=0.5 (small effect), ​=1:

=Φ(0.24) ≈ 60%.

**Key Assumptions**

1. **Microbiome:**
   * Normally distributed differences (Shannon/SCFA changes).
   * ICC = 0.3 for repeated measures.
2. **FMT Tumor Model:**
   * Linear mixed model accounts for donor-clustered effects.
   * Tumor volumes log-transformed if skewed.
3. **Dropout:**
   * Final *n* = 16 still achieves **>75% power** for *d* ≥ 0.7.

A graph with lines and dots

AI-generated content may be incorrect.A graph of a bar and a number of microbes

AI-generated content may be incorrect.